||Review of the Indian market of anti-tuberculosis drugs
: focus on the utilisation of Rifampicin-based products
||INT J TB & LUNG DIS 1999, 3 (Suppl), S289-291
There is a need to better understand the extent
of the utilisation of Rifampicin in the market, particularly in
Fixed-Dose Combinations (FDC). The objective of the study was to
review the Indian market of anti-TB drugs, as this is the largest
single market in the world of this therapeutic class where about
50% of global consumption of Rifampicin takes place. The study was
designed to review and analyse the sales data proffered by the Indian
market audit. Estimated data relating to public sector product usage
were utilised in order to obtain a more complete scenario.
There are 3 Indian Rifampicin fermentation plants
with a total capacity of about 340 metric tons, supplying to the
demand of local market and export activities. It is estimated that
there was a total consumption of 250-275 metric tons of Rifampicin
in 1998. Other raw materials for the formulation of anti-TB drugs
such as Isoniazid, Pyrazinamide and Ethambutol are also produced
in India for local consumption as also for export. FDCs were particularly
produced in India with sales of about US$139 million in 1998 (public
sector - $60 million HMR/India estimate), private sector
- $70 million.
Sales for Lupin Laboratories represents 41% of
the private market followed by Novartis with a market share of 10%.
Rifampicin + INH FDC group is the largest of all anti-TB drug sub
groups. Exactly 50% of this market sub-group are represented by
the sales of two leading double FDC brand names worth US$25.8 million.
Triple FDC (Rifampicin + INH + Pyrazinamide) sales of US$10.4 million
are characterised by a large variety of different dosage ratios
for the 3 drugs and market leader has the market share of 14%. Two
quadruple FDCs sales in India are limited and the AKT FD brand has
87% of this sub-group for the time being. Both the public and private
sectors of anti-TB drugs are likely to grow in the future in volume
and value and the Indian pharmaceutical industry is very active
in the export of raw materials.
|KEY WORDS : INDIAN MARKET; RIFAMPICIN; FIXED DOSE COMBINATION;
HEALTH ECONOMICS; ITALY.